“Vector” announced preclinical trials of another vaccine against COVID-19

Photo of author

By admin

The Rospotrebnadzor “Vector” Center is preparing for expanded preclinical trials of another influenza virus-based COVID-19 vaccine. The general director of the center Rinat Maksyutov announced this on December 19.

According to him, the vaccine is made on the basis of a recombinant influenza virus, which, as experts hope, will protect against seasonal variants of influenza and against the new coronavirus. The prototype of the drug was tested on laboratory animals.

“It has shown its immunogenicity, and now a decision is being made to switch to extended preclinical studies,” he said on the air of the Russia 1 TV channel.

As Russian President Vladimir Putin said the day before, new Russian vaccines against coronavirus should appear in the near future. The head of Rospotrebnadzor Anna Popova said on December 16 that Russian scientists are working on the creation of 26 vaccine variants against the new infection.

The first coronavirus vaccine in Russia and the world was registered on August 11. Sputnik V was developed by specialists from the Gamaleya Center.

The registration of the second vaccine became known on October 14. It was named “EpiVacCorona” and was developed by the state research center “Vector”.

Another vaccine – from the Chumakov Federal Scientific Center for Research and Development of Immunobiological Products – may be registered in December.

Up-to-date information on the situation with the coronavirus is available on the websites of stopcoronavirus.rf and access vsem.rf, as well as by the hashtag #WeVotre. Coronavirus hotline: 8 (800) 2000-112.

Leave a Comment